Recent advances in selective serotonergic agents

被引：9

作者：

Childers, WE ^{[1
]}

Robichaud, AJ ^{[1
]}

机构：

[1] Wyeth Ayerst Res, Chem & Screening Sci, Princeton, NJ 08543 USA

来源：

ANNUAL REPORTS IN MEDICINAL CHEMISTRY, VOL 40 | 2005年 / 40卷

关键词：

D O I：

10.1016/S0065-7743(05)40002-0

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

Arguably, serotonin (5-HT) is one of the most studied of the neurotransmitters. The identification of 5-HT as a vasoconstricting agent over 50 years ago [1] and the discovery that more than one subtype of 5-HT receptor exists [2] marked the beginning of a monumental effort that has extended our knowledge, not only of 5-HT receptors, but of G-protein coupled receptors (GPCR's) in general. There are presently fourteen known 5-HT receptor subtypes, some of which exist as multiple splice variants. They are located both centrally and peripherally, influence a number of physiological functions, and are implicated in many disease states [3]. Numerous reports describe ligands that bind to multiple 5-HT receptor subtypes with high affinity or agents that interact with the 5-HT uptake site. The recent literature on these pursuits is extensive and merits review in its own right. The goal of this chapter is to summarize recent advances in selective 5-HT receptor modulators [4,5]. © 2005 Elsevier Inc. All rights reserved.

引用

页码：17 / 33

页数：17

共 120 条

[11] The 5-hydroxytryptamine, receptor-selective radioligand [3H]Ro 63-0563 labels 5-hydroxytryptamine receptor binding sites in rat and porcine striatum [J].

Boess, FG ;

Riemer, C ;

Bös, M ;

Bentley, J ;

Bourson, A ;

Sleight, AJ .

MOLECULAR PHARMACOLOGY, 1998, 54 (03) :577-583

[12] Novel potent 5-HT3 receptor Ligands based on the pyrrolidone structure:: Synthesis, biological evaluation, and computational rationalization of the ligand-receptor interaction modalities [J].

Cappelli, A ;

Anzini, M ;

Vomero, S ;

Mennuni, L ;

Makovec, F ;

Doucet, E ;

Hamon, M ;

Menziani, MC ;

De Benedetti, PG ;

Giorgi, G ;

Ghelardini, C ;

Collina, S .

BIOORGANIC & MEDICINAL CHEMISTRY, 2002, 10 (03) :779-801

[13]

CHILDERS WE, IN PRESS J MED CHEM

[14] Identification of a 5-HT4 receptor antagonist clinical candidate through side-chain modification [J].

Clark, RD ;

Jahangir, A ;

Alam, M ;

Rocha, C ;

Lin, L ;

Bjorner, B ;

Nguyen, K ;

Grady, C ;

Williams, TJ ;

Stepan, G ;

Tang, HM ;

Ford, APDW .

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2005, 15 (06) :1697-1700

[15]

CLINESCHMIDT BV, 1985, J PHARMACOL EXP THER, V235, P696

[16] Discovery of 5-arylsulfonamido-3(pyrrolidin-2-ylmethyl)-1H-indole derivatives as potent, selective 5-HT6 receptor agonists and antagonists [J].

Cole, DC ;

Lennox, WJ ;

Lombardi, S ;

Ellingboe, JW ;

Bernotas, RC ;

Tawa, GJ ;

Mazandarani, H ;

Smith, DL ;

Zhang, GM ;

Coupet, J ;

Schechter, LE .

JOURNAL OF MEDICINAL CHEMISTRY, 2005, 48 (02) :353-356

[17] N1-arylsulfonyl-3-(1,2,3,6-tetrahydropyridin-4-yl)-1H-indole derivatives are potent and selective 5-HT6 receptor antagonists [J].

Cole, DC ;

Ellingboe, JW ;

Lennox, WJ ;

Mazandarani, H ;

Smith, DL ;

Stock, JR ;

Zhang, GM ;

Zhou, P ;

Schechter, LE .

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2005, 15 (02) :379-383

[18] 5-HT3 Receptors [J].

Costall, Brenda ;

Naylor, Robert J. .

CNS & NEUROLOGICAL DISORDERS-DRUG TARGETS, 2004, 3 (01) :27-37

[19] New arylpiperazine derivatives as antagonists of the human cloned 5-HT4 receptor isoforms [J].

Curtet, S ;

Soulier, JL ;

Zahradnik, I ;

Giner, M ;

Berque-Bestel, I ;

Mialet, J ;

Lezoualc'h, F ;

Donzeau-Gouge, P ;

Sicsic, S ;

Fischmeister, R ;

Langlois, M .

JOURNAL OF MEDICINAL CHEMISTRY, 2000, 43 (20) :3761-3769

[20]

Dourish CT, 1995, OBES RES, V3, pS449, DOI 10.1002/j.1550-8528.1995.tb00212.x

← 1 2 3 4 5 6 7 8 9 10 →